

# DETECTION OF ADVERSE NEUROPSYCHIATRIC REACTIONS ASSOCIATED WITH ABIRATERONE AND ENZALUTAMIDE TREATMENTS IN THE HOSPITAL.

A.M. VALLE DÍAZ DE LA GUARDIA<sup>1</sup>, R. ÁLVAREZ SÁNCHEZ<sup>2</sup>, A. JIMÉNEZ<sup>1</sup>, E. GONZÁLEZ<sup>1</sup>.

<sup>1</sup>HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES, FARMACIA HOSPITALARIA, GRANADA, SPAIN.

<sup>2</sup>HOSPITAL UNIVERSITARIO SAN CECILIO, FARMACIA HOSPITALARIA, GRANADA, SPAIN.

## Background and purpose

Enzalutamide (ENZ) and abiraterone acetate (AA) can cause neurological and psychiatric adverse effects. Some publications suggest that this type of reactions are more frequent with ENZ than with AA. The aim of this study is to check the prevalence in patients treated in our hospital.

## Material and methods

We selected patients in treatment with ENZ or with AA from January 2015 to September 2018. Clinical data were obtained by consulting their clinical history and the pharmacy service's computer program.

### Signs / symptoms identified as adverse neuropsychiatric reaction:

- restless leg
- syndrome
- anxiety
- headache
- insomnia
- seizures
- falls
- dizziness
- hallucinations
- memory impairment.

## Results

→ In the AA group (53 patients) were detected 12 patients (22.6%) with adverse neuropsychiatric-type reactions: falls (8 patients), insomnia (6 patients), headache (6 patients) and memory loss (4 patients).

→ The ENZ group (61 patients) showed similar data, in 14 patients (22.9%) this type of alterations appeared: insomnia (10 patients), headache (6 patients), falls (6 patients) and memory loss (5 patients).

## Conclusion

Both drugs show the same profile in terms of adverse neuropsychiatric reactions. But it is true that more studies are needed to determine if these reactions are due to these drugs or to other factors such as age, the evolution of the disease or the patient's social situation.